A round of financing involving Medtronic, GlaxoSmithKline's Action Potential Venture Capital and other investors has brought in almost $40 million for Saluda Medical. The proceeds will be used for a US pivotal trial of the company's Evoke closed-loop spinal cord stimulation device, as well as for commercialization in the EU and Australia.
Funding round pulls in nearly $40M for Saluda Medical
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.